MedTrace Logo

Peptide Vaccination in Treating Patients With Esophageal Cancer (STF-II)

NCT01267578 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2010-12-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate overall survival and immunological monitoring for peptide vaccination therapy using novel cancer testis antigens (STF-II) for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma

Conditions

  • Esophageal Cancer

Interventions

BIOLOGICAL

vaccination

Biological/Vaccine: URLC10, CDCA1, and KOC1 peptides

Sponsors & Collaborators

  • Human Genome Center, Institute of Medical Science, University of Tokyo

    collaborator OTHER

  • University of Yamanashi

    lead OTHER

Principal Investigators

  • Koji Kono, PhD, MD · University of Yamanashi, First Department of Surgery

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-05-31
Completion
2012-05-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01267578 on ClinicalTrials.gov